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Importance: Migraine is a common disorder and a frequent cause of medical consultation in children. Many
childhood episodic syndromes have been described as common precursors of migraine.
Objective: To review current knowledge on migraine and childhood episodic syndromes, and to discuss future
directions for research and clinical practice.
Findings: For most children it is difficult to describe a headache and fully verbalize symptoms such as photophobia
and phonophobia that must be inferred from behaviour. Classical migraine features are rare before the age of
6 years, but some migraine-related syndromes have been described. Benign paroxysmal torticollis of infancy, benign
paroxysmal vertigo of childhood, cyclic vomiting syndrome and abdominal migraine are currently classified as
childhood episodic syndromes, and therefore common precursors of migraine. A strong association between infantile
colic and migraine has recently been reported. There are similarities between children with episodic syndromes and
children with migraine, regarding social and demographic factors, precipitating and relieving factors, and accompanying
gastrointestinal, neurologic, and vasomotor features. The real pathophysiological mechanisms of migraine are not fully
understood. Current data obtained through molecular and functional studies provide a complex model in which
vascular and neurologic events cooperate in the pathogenesis of migraine attacks. Genetic factors causing disturbances
in neuronal ion channels, make a migraineur more sensitive to multiple trigger factors that activate the nociception
cascade. The expanding knowledge on migraine genetics and pathophysiology may be applicable to childhood
episodic syndromes. Migraine preventive strategies are particularly important in children, and could be beneficial in
childhood episodic syndromes. Nonspecific analgesics like ibuprofen and acetaminophen are widely used in pediatrics
to control pain and have been found to be effective also in the treatment of acute migraine attacks. Triptans are the
specific fist-line drugs for acute migraine treatment.
Conclusions and relevance: Migraine phenotype differs somewhat in the developing brain, and childhood episodic
syndromes may arise before typical migraine headache. Diagnosing pediatric migraine may be difficult because of
children’s language and cognitive abilities. The risk of underestimating migraine in pediatric age is high. An adequate
diagnosis is important to maintain a good quality of life and to avoid inappropriate therapy.
Keywords: Infantile colic, Migraine, Cyclic vomiting, Recurrent abdominal pain, Functional abdominal pain, Torticollis* Correspondence: luigi.titomanlio@rdb.aphp.fr
3Department of Pediatric Emergency Care, APHP-Hospital Robert Debré,
Paris, France
4Pediatric Migraine and Neurovascular Diseases Unit, APHP-Hospital Robert
Debré, Paris, France
Full list of author information is available at the end of the article
© 2014 Spiri et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Spiri et al. Italian Journal of Pediatrics 2014, 40:92 Page 2 of 11
http://www.ijponline.net/content/40/1/92Background
Headache is the most common pain condition in
children and adolescents visiting a pediatrician [1] and
migraine is one of the most common causes of primary
headache in childhood [2]. Its prevalence increases
throughout childhood, affecting 1-3% of 3 to 7 year-olds,
4-11% of 7 to 11 year-olds, and 8-28% of teenagers (13-
18 years old) [3]. Migraine is a neurovascular disorder
with a genetic background and several genes have been
identified as being direct causal or associated agents [4].
First degree relatives of subjects with migraine have a
1.9 times higher risk of developing migraine compared
to the general population [5,6] and the concordance rate
for migraine with aura in monozygotic twins is 34%
compared to 12% in dizygotic twins [7], suggesting the
importance of genetic factors in migraine development.
Migraine is disabling at all ages; in children and ado-
lescents it can be accompanied by significant disability,
such as school absenteeism, low-quality performance
and impaired emotional functioning [8]. Children with
recurrent headache can suffer from depression, anxiety
and often from sleep disorders and they have the ten-
dency to feel dizzy [9]. Poor performance at school is
more likely to be present in children with episodic and
chronic migraine, in comparison to children without
headaches. School performance is significantly influenced
by severity and duration of headache attacks, by abnormal
scores of mental health, and by nausea, as well as by
headache frequency and use of analgesics [10].
We aimed at reviewing current knowledge and concerns
on migraine and related episodic syndromes. To identify
articles a literature search was carried out in PubMed and
the electronic Science Direct for all studies published until
July 31st, 2014. The keywords searched for were “migraine
and children”, ”headache and children”, and “episodic
syndromes and migraine”. Studies were included if they
focused on the pediatric population, if they were published
in peer reviewed journals and written in English.
Migraine diagnosis and current state of clinical practice
Headache diagnosis is usually conducted on the basis of
the International Headache Society (IHS) criteria. After
two editions (respectively in 1988 and in 2004) [11] the
latest International Classification of Headache Disorders
(ICHD-III beta) is available [12].
Diagnostic International Headache Society criteria for
migraine without aura and migraine with aura
Migraine without aura
A. At least 5 attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 hours (untreated or
unsuccessfully treated). In children, attacks may last
2-72 hours.C. Headache has at least two of the following
characteristics:
1. unilateral location (commonly bilateral in young
children)
2. pulsating quality
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of routine
physical activity
D. During headache at least one of the following:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not attributed to another disorder
Migraine with typical aura
A. At least 2 attacks fulfilling criteria B-D
B. Aura consisting of at least one of the following, but
no motor weakness:
1. fully reversible visual symptoms including positive
features (e.g., flickering lights, spots or lines) and/
or negative features (i.e., loss of vision)
2. fully reversible sensory symptoms including
positive features (i.e., pins and needles) and/or
negative features (i.e., numbness)
3. fully reversible dysphasic speech disturbance
C. At least two of the following:
1. homonymous visual symptoms and/or unilateral
sensory symptoms
2. at least one aura symptom develops gradually
over ≥5 minutes and/or different aura symptoms
occur in succession over ≥5 minutes
3. each symptom lasts ≥5 and ≤60 minutes
D. Headache fulfilling criteria B-D for Migraine without
aura begins during the aura or follows aura within
60 minutes
E. Not attributed to another disorder
Unlike the previous editions that were mostly based
on the opinions of experts, for the latest edition there is
substantial evidence available for the classification work.
Already in the ICHD-II, criteria for migraine had been
specifically adopted for use in children allowing a higher
number of pediatric patients to be classified. The two
most frequent subtypes of migraine in pediatric popula-
tion are respectively migraine without aura and migraine
with aura. Aura is defined as a transient focal neuro-
logical phenomenon that occurs before or during a
headache. It appears gradually over several minutes and
generally lasts less than 1 hour. Symptoms can be visual,
sensory or motor and many children experience more
than one symptom.
Migraine is the second most common cause of chronic
recurrent headache in school children, with a prevalence
ranging from 3.2 to 14.5% [13]. However, epidemiologic
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children it was not possible to perform a specific pri-
mary headache diagnosis [14-16]. Criteria for migraine
diagnosis in children and adolescents are confirmed in
ICHD-III beta except for duration of attacks. For the
ICHD-II classification migraine may last as little as 1 hour
whereas in the new classification, attacks may last from 2
to 72 hours (instead of a minimum of 4 hours in adults):
the evidence for untreated migraine with a duration infer-
ior than 2 hours in children has not been substantiated.
The younger the child is, the more atypical the symp-
toms are. Migraine in preschool children may lack
throbbing characteristics, unilaterality and full-blown
autonomic symptoms [9] but its paroxysmal and peri-
odic occurrence is observed as the outstanding feature
in all migraine manifestations at this age [17]. Children
often experience a bilateral pain, usually in frontal or
temporal regions, poorly defined and invariably accom-
panied by pallor, nausea and vomiting. The unilateral
pain, typically referred by adults, usually emerges in late
adolescence or early adult life. Occipital headache is not
common in children, in which case a possible organic
pathology should be suspected. Pain quality is different to
that of adults because it is often reported as constrictive-
oppressive and for most children it is difficult to describe
a headache using words like “throbbing” or to fully
verbalize symptoms such as photophobia and phonopho-
bia that must be inferred from behaviour [18]. Cranial
autonomic symptoms, mainly ocular and nasal (lacrima-
tion, conjunctival injection, nasal congestion, rhinorrhoea),
are frequently found in pediatric migraine, often leading
to a misdiagnosis of sinus headache and delaying appro-
priate migraine therapy [19].
In children, migraine with aura is less frequent than
migraine without aura. The most common aura symp-
toms in children are visual and sensorial disorders. Vis-
ual aura is typically referred as a “fortification spectrum”
characterized by zigzag lines close to the fixation point
that then gradually expand assuming the appearance of
a convex shape displaced laterally and twinkling. Vision
becomes increasingly blurred and children can experi-
ence transient hemianopsia or a complete transient
unilateral blindness (amaurosis fugax). Sensorial aura is
often characterized by unilateral paresthesia, hemiparesis
and dysphasia. Children typically describe many small
pinpricks that slowly move from the place of origin to
wider regions as the arm, the leg or the face.
During the last two decades, modifications of ICHD
criteria permitted to improve sensitivity of migraine
diagnosis in children up to 84.4% [20,21] but studies
demonstrate that there still are deficiencies in fully rec-
ognizing pediatric headache and Ballottin demonstrated
that the ICHD-II criteria are poorly applicable to chil-
dren below the age of 6 years [22]. Further studies areneeded to define the applicability of ICHD-III criteria in
the pediatric population and in order to develop alterna-
tive and more specific criteria for children. A recent
study conducted by De Carlo found that 34.6% of pediatric
migraine patients have osmophobia and when this symp-
tom was utilized in the diagnostic process as an additional
associated symptom, there was an increase in the percent-
age of subjects with a migraine diagnosis [23].
Migraine pathogenetic hypothesis
Eight genes have been so far identified as being associ-
ated with common migraine (i.e. with and without aura)
[24,25]. MTDH, LRP1, PRDM16, MEF2D, ASTN2, and
PHACTR1 are involved in neuronal and glutamatergic
pathways; TGFBR is responsible for the maintenance of
vascular integrity and function whereas TRPM8 is in-
volved in pain signalling pathways [26]. Many advances
in the understanding of migraine pathophysiology have
been possible through to the study of the rare autosominal
dominant Familial hemiplegic migraine (FHM). Gene
mutations in membrane ion channel transport proteins,
including CACNA1A (P/Q-type voltage-gated calcium
channel), ATP1A2 (sodium-potassium ATPase), SCN1A
(voltage-gated sodium channel), and PRRT2 (proline-rich
transmembrane protein 2) lead to FHM. More recently,
mutations in SLC4A4 [27], encoding the Na+-HCO3
-
cotransporter NBCe1, have been identified [28]. Multiple
conventional and advanced MRI techniques including sus-
ceptibility weighted imaging (SWI) play a key role during
an Hemiplegic Migraine attack to exclude acute arterial
ischemic stroke; the transient unilateral motor weakness
that characterizes this rare type of migraine usually lasts
for a few hours and neuroimaging abnormalities com-
pletely resolve within 24 hrs after the attack onset [29].
The real pathophysiological mechanisms of migraine
are not fully understood. For decades, the throbbing
pain during migraine headache was thought to originate
from dilated cranial arteries: unilateral stimulation of
extra cranial and intracranial arteries was in fact associ-
ated with ipsilateral head pain [30]. During the past two
decades the focus on this vascular hypothesis has dimin-
ished and neuronal mechanisms have been suggested as
generators of migraine headache, without abnormal acti-
vation of perivascular sensory fibers [31]. More recently,
current molecular and functional studies, conducted
using PET, intracarotid SPECT (Single-Photon Emission
Computed Tomography), MRA (magnetic resonance
angiography), functional MRI and TMS (Transcranial
Magnetic Stimulation), allowed to formulate a complex
theory in which vascular and neurologic events cooper-
ate in the pathogenesis of migraine attacks without aura
[32]. Afferent innervations of intracranial blood vessels,
forming the Trigemino-Vascular System (TVS), are the
essential substrate for migraine pain in this intricate
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are supposed to initiate the neuronal excitation that
leads to clinical manifestations in patients with a genetic
vulnerability to migraine. Migraine-specific triggers, as
foods containing vasoactive amines (e.g.: tyramine and
phenylethylamine), hormonal fluctuation, psychological
and environmental triggers as stress, worse mood [34],
anxiety, fatigue, sleep deprivation, light, and rapid tem-
perature changes, induce the activation of trigeminal nerve
sensory fibers, which innervate intracranial blood vessels,
by dilatation of cranial blood vessels. However, Amin in a
recent study conducted using MRA during spontaneous
unilateral migraine attacks, demonstrates that migraine
pain is not accompanied by extracranial arterial dilatation
but by only slight intracranial dilatation [35].
Therefore, the initial events that lead to the activation
of nociception cascade are still not entirely clear. Brain-
stem network activation determines the release of vaso-
active peptides such as CGRP (calcitonin gene-related
peptide) and substance P from trigeminal fibers, indu-
cing vasodilation and neurogenic inflammation [36].
This inflammation increases the trigeminal sensory fi-
bers activation and perpetuates the release of vasoactive
peptides (sustaining the transmission of pain impulses to
the brain) over a time span of hours to days in corres-
pondence with the duration of a typical migraine epi-
sode. The cortical spreading depression (CSD) theory isFigure 1 Migraine pain generation. Migraine triggers initiate the neuron
genetic vulnerability to migraine. Cortical spreading depression (CSD) trigg
turn activates trigeminal (TG) afferents within the trigemino-vascular system
neurons. Signals are transduced to the trigeminal nucleus caudalis (TNC), w
such as the periaqueductal gray, the locus coeruleus and the raphe. The TN
is generated.thought to explain generation of migraine attacks with
aura. Transcranial magnetic stimulation and functional
MRI studies have shown that at baseline, migraneurs
have a state of neuronal hyperexcitability in their cere-
bral cortex, especially in the occipital region. This sug-
gests that the initial phase of a migraine attack with aura
is a wave of cortical spreading depression which is asso-
ciated with the suppression of spontaneous EEG activity
and regional oligemia. CSD begins in the occipital region
and moving anteriorly, stops at the central sulcus, and
then spreads ventrally to the meningeal trigeminal fibers.
Once the CSD occurs, H + and K + diffuse to the pia mater
and activate meningeal nociceptors (C-fibers) which re-
lease pro-inflammatory agents after TVS activation [37].
Recent studies have suggested that some types of
migraine may be related to a mitochondrial dysfunction
[38]. Biochemical evidence supporting this relationship
consists in the fact that abnormal mitochondrial func-
tion determines a high intracellular penetration of cal-
cium, an excessive production of free radicals and a
deficient oxidative phosphorylation which ultimately
causes energy failure in neurons and astrocytes. These
events can trigger migraine mechanisms ultimately caus-
ing CSD. Further studies are required to investigate a
possible relationship between mtDNA and migraine.
Current data therefore provide a complex model in
which genetic factors, causing disturbances in neuronalal excitation that leads to clinical manifestations in children with a
ers plasma protein extravasation from cerebral blood vessels, which in
(TVS). Gene mutations could reduce the threshold for firing of TG
hich receives modulatory inputs from other brainstem nuclei (BN),
C projects to rostral brain areas, where the perception of pain
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tiple trigger factors. The generation of migraine pain is
probably a consequence of multiple pathophysiological
changes in meningeal tissues, TG (Trigeminal Ganglion),
trigeminal brainstem nuclei and descending inhibitory
systems that are still not fully clarified and are worth
further studies. The result is an activation of the brain-
stem which is the principal vascular tone regulating and
nociceptive processing center. Activation of the brain-
stem also regulates the nociceptive transition to higher
structures of the central nervous system (CNS), as the
thalamus and the cortex [39].
Treatment of migraine
An appropriate migraine management requires filling in
a diary for at least one month in order to collect more
detailed information on headache characteristics and
associated signs.
Migraine preventive strategies are particularly important
in children, and could be beneficial in childhood episodic
syndromes. Prevention of migraine attacks includes trigger
management and adequate pharmacologic treatments,
when needed. Frequent migraine triggers, such as physical
and mental stress, school problems, irregular and un-
healthy lifestyle habits [40] can be removed or modified. A
correct lifestyle with appropriate nutritional and sleeping
habits and regular physical activity are the first steps to
achieve a high quality migraine therapy. Distraction tech-
niques, relaxation and biofeedback are also valuable tools
that pediatricians must take into account in managing
migraine [41-44].
Acute pharmacological treatment consists in using
drugs only during a migraine attack. Its goal is to com-
pletely eliminate pain and related symptoms. Nonspe-
cific analgesics like ibuprofen and acetaminophen are
widely used in pediatrics in order to control pain and
have been studied in randomized, double-blind, placebo-
controlled trials and found to be effective also in the
treatment of acute migraine attacks [45,46]. Triptans are
the specific fist-line drugs for acute migraine treatment
[47,48]. Although nasal spray sumatriptan [49-51] and
zolmitriptan [52] have positive randomized trials in chil-
dren, only almotriptan [53] (in adolescents aged 12-17
years) and rizatriptan [54] (for 6-17 years olds) are now
FDA-approved for pediatric use. Generally ergot alkaloid
dihydroergotamine [55], dopamine receptor antagonists
[56] and opioids are not considered first-line treatment of
acute migraine in children and adolescents because of their
potential side-effects and, especially regarding opioids, be-
cause of their association with the development of chronic
migraine and medication overuse headache [57,58].
Sheridan et al. [59] recently described the variability in
diagnostic testing and treatment of headaches in chil-
dren presenting to the emergency department and foundthat despite evidence based clinical guidelines, a large
number of children with migraine continued to receive
opioids as acute treatment.
Pharmacologic preventive treatment is generally pro-
posed when migraine attacks occur once a week or
whenever the attacks are particularly long and debilitat-
ing [60]. Among migraine preventives, topiramate [61-63],
flunarizine [64], amitriptyline [65,66] and divalproex so-
dium [67,68] have evidence of efficacy and safety support-
ing their use in children.
Current state of clinical practice and diagnosis of
childhood episodic syndromes
A range of symptoms and signs (such as vertigo, torti-
collis, visual and sensorimotor disturbances, anorexia,
recurrent abdominal pain, nausea and vomiting, motion
sickness, sleep and behavioural disorders) may occur in
children in the absence of headache and may precede
the development of typical migraine manifestations by
several years [69,70].
Benign paroxysmal torticollis, benign paroxysmal ver-
tigo, cyclic vomiting syndrome and abdominal migraine
are defined as “episodic syndromes that may be associ-
ated with migraine” in ICHD-III beta [12]. In 2001, Jan
documented a relationship between infantile colic and
migraine [71]. His data suggested that children with
migraine were more likely to have a personal history of
infantile colic and a family history of infantile colic or
migraine in any of the first-degree relatives. Children
with a history of infantile colic were also more likely to
have a positive family history for migraine. Jan supposed
that pain and crying in some genetically predisposed
infants could represent a form of infantile migraine with
an age specific expression. We recently confirmed the
association between migraine and infantile colic with a
multicenter case-control study [72], suggesting that colic
may represent one of the earliest clinical manifestations
of migraine such as the episodic syndromes included in
ICHD-III beta [18] (Figure 2). Paroxysmal tonic up gaze
[73], recurrent abdominal pain [74], motion sickness
[75], recurrent limb pain [76], and parasomnias [77] are
not clearly associated with migraine and are not yet
universally accepted as precursors of migraine.
Childhood episodic syndromes are characterized by
reversible and stereotyped attacks, with a periodic occur-
rence. Children are healthy and neurologically normal
between attacks [78-80]. There are strong similarities
between children with episodic syndromes and children
with migraine, regarding social and demographic factors,
precipitating and relieving factors, and accompanying
gastrointestinal, neurologic, and vasomotor features [17].
Children with episodic syndromes often have a positive
family history for migraine and those with earlier-onset
episodic syndromes may eventually develop migraine in
Figure 2 Age-related expression of childhood episodic syndromes common precursors of migraine. * = infantile colic is actually considered as
an episodic syndrome that may be associated with migraine.
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observed with migraine-specific drugs (triptans) further
confirms the association of episodic syndromes with mi-
graine. Diagnosis of childhood episodic syndrome is one
of exclusion and involves a careful anamnesis, physical
examination and appropriate neurodiagnostic studies to
exclude other discernable causes as epilepsy, metabolic
disorders, ischemic events or psychological disorders.
Infant colic
Recent research suggests that infantile colic may be a
childhood episodic syndrome [72,80]. Infantile colic affects
5-19% of babies during their first months of life and, ac-
cording to Wessel criteria, it is characterized by inconsol-
able crying and fussing for more than 3 hours per day,
more than 3 days per week and for more than 3 weeks in
an otherwise healthy and well-fed infant [82-84].
Benign paroxysmal torticollis of infancy (ICHD III beta 1.6.3)
Benign paroxysmal torticollis is a rare paroxismal dys-
kinesia that appears commonly around the age of 2 to 8
months. It is characterized by recurrent and stereotyped
attacks of abnormal inclination or rotation of the head,
occasionally accompanied by vomiting and ataxia. Torti-
collis is secondary to cervical dystonia although it may
occur in association with other dystonic features such as
truncal and pelvic asymmetrical posturing [78]. During
an episode it is possible to observe pallor, photophobia,
ataxia, drowsiness and headache which resemble mi-
graine features. The episodes often last from several
hours to days, and have a spontaneous resolution. Typic-
ally, the attacks frequency and duration decline as the
child grows older with a definitive resolution at the age
of 5 years [85].
Benign paroxysmal vertigo of childhood (ICHD III beta 1.6.2)
Benign paroxysmal vertigo occurs as a sudden attack of
unexplained fright accompanied by balance troubles oreven falls [86]. The onset is characterized by a sudden
expression of anxiety and fear followed by attempting to
grasp a person or any other support standing nearby.
Autonomic signs such as dizziness, nausea, pallor, perspir-
ation, photophobia and phonophobia may accompany ver-
tigo. Vomiting and nystagmus are common. The episodes,
lasting generally less than 5 minutes, are never associated
with loss of consciousness [87]. The onset is between
the age of 2 to 4 years and the frequency of attacks var-
ies from once a day to once every 1-3 months [88]. Typ-
ically, children suffering from benign paroxysmal vertigo
have a positive family history for migraine and a positive
family and personal history for motion sickness. Some
patients may develop other childhood episodic syn-
dromes such as cyclic vomiting or recurrent abdominal
pain [89]. Some authors suggest that benign paroxysmal
vertigo may constitute an early-onset variant of basilar-
type migraine [90].
Cyclic vomiting syndrome (ICHD III beta 1.6.1.1)
This syndrome is characterized by recurrent and self-
limited episodes of severe nausea and vomiting, inter-
spersed with symptom-free periods. Affected children
usually experience a stereotypical pattern of events in
which a prodromal phase is followed by an emetic and a
recovery phase [91]. During the prodromal phase, lasting
about 1.5 hours, children experience an impending epi-
sode characterized by worsening nausea and a dramatic
autonomic dysfunction with decreased muscle tone, pal-
lor, lethargy and apathy. This clinical picture evolves into
emetic phase in which vomiting is typically intense, often
bilious, and accompanied by persistent nausea, anorexia,
retching, increased salivation, abdominal pain, headache,
pallor, photophobia and phonophobia. This phase lasts
an average of 24 hours before the beginning of the
recovery phase characterized by remission of nausea and
resumption of normal appetite, of oral intake and of a
baseline clinical status [92].
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ally before the age of 6 years and the frequency of epi-
sodes varies between 3 and 12 per year [93]. The median
age for resolution of vomiting episodes is 10 years and
75% of affected children will develop migraine by the
age of 18 years [94].Abdominal migraine (ICHD III beta 1.6.1.2)
Abdominal migraine is characterized by recurrent,
acute-onset abdominal pain lasting for hours or days and
accompanied by dysautonomic signs such as pallor, dark
shadows under the eyes, flushing, anorexia and vomiting
[95]. Affected children experience a dull or colicky pain
generally localized in periumbelical region. During the
inter-episodic period children are completely healthy [96].
The onset of abdominal migraine occurs at the age of 7
years with a peak of prevalence at 10 years of age [97].
Some studies suggest that abdominal migraine could per-
sist into adult life and 70% of affected children develop mi-
graine as they grow older. There are similarities between
affected children and children with migraine regarding
demographic, social, clinical and familial features. More-
over, children with abdominal migraine manifest similar
triggering events such as psychological stress, physical ex-
haustion and motion sickness [93]. Sometimes, a preced-
ing aura occurs with visual disturbance, flashing lights,
numbness or a tingling sensation, slurred speech or
muscle weakness.Childhood episodic syndromes pathogenetic hypothesis
The expanding knowledge on migraine genetics and
pathophysiology may be applicable to childhood episodic
syndromes. According to the fact that both gut and ner-
vous system are derived from the same embryologic
tissues and that the enteric nervous system and the CNS
exert direct effects on each other [98], it has been
hypothesized that pathogenesis of abdominal migraine
consists in an increased arousal in the CNS in response
to triggers, thus releasing neuropeptides and neurotras-
mitters that lead to dysregulation of the gastrointestinal
system. This could also explain the recent demonstrated
association between infantile colic and migraine. We
supposed that infants with colic experience a sensitiza-
tion of the perivascular nerve terminals in the gut, as
happens in the brain during a migraine attack [72]. The
potential role of molecules as CGRP, involved in modu-
lation of sensory activity in both the brain and the gut,
remains to be elucidated [99]. A disrupted sleep pattern
might be a trigger for colic symptoms, as it is often ob-
served in patients with migraine [100]. Cyclic vomiting
syndrome is also believed to be a brain-gut disorder
involving neuroendocrine pathways in genetically pre-
disposed individuals [101,102]. The same dysregulatedpathways may be involved in symptoms accompanying
migraine attacks as nausea and vomiting [103].
Mutations in the CACNA1A and PRRT2 genes, which
are associated with FHM, have been found in some
patients with benign paroxysmal torticollis and benign
paroxysmal vertigo [85,104], thus confirming their link
to migraine. Transitory vascular disturbances in cerebellar
cortex, where CACNA1A is abundantly expressed, were
demonstrated in temporal cortex and the vestibular nuclei
respectively during episodes of torticollis and vertigo [105].
Treatment of episodic syndromes
No specific treatment exists for infant colic. Positive
results have been obtained by decreasing the infant’s
level of stimulation during acute episodes [106,67] as it
is observed in migraine. There are no known effective
treatments for both benign paroxysmal torticollis and
vertigo. Antiemetics could be considered in the acute
phase if there is significant vomiting. Acute treatment of
cyclic vomiting syndrome typically consists in rehydration
and antiemetics [18]. A favourable response to subcutane-
ous and nasal spray sumatriptan has been reported [68]
and represents another argument in favour of a rela-
tionship with migraine. Abdominal migraine generally
responds to triptans [106]. Preventive treatment with
flunarizine can be considered if attacks are frequent or
long-lasting [107].
Remaining concerns and future directions for migraine
and related syndromes
ICHD criteria are useful to simplify and standardize
diagnostic approach to primary headache, and represent
the gold standard for diagnosing migraine and childhood
episodic syndromes. However, applying diagnostic cri-
teria to children can be difficult because the course of
the disease and the description of the acute events are
often inaccurate, especially regarding parameters like
duration, intensity and localization [108]. The ICHD-II
criteria (and probably the new ICHD-III beta criteria
too) are still poorly applicable to children under the age
of 6 years [22] and it is likely that infantile colic and
osmophobia will be considered respectively as a precur-
sor and an alternative symptom of migraine in future
revisions, because of the strong association observed.
Modification of the criteria in order to include bilateral
headache, shorter duration of the attacks, nausea and/or
vomiting associated with at least two out of five other
associated symptoms (photophobia, phonophobia, diffi-
culty in thinking, light-headedness or fatigue) which
must be derived form behavior, in addition to the usual
description of moderate to severe pain of a throbbing or
pulsating nature, worsening or limiting physical activity,
improved accuracy of migraine diagnosis in children
[20,22]. Indeed, when migraine is under-diagnosed the
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strated that 42.5% of subjects with headache use medi-
cines. 68.2% of these reported that medicines for headache
were always available at home, and 22.2% were allowed to
use these without asking for permission [109]. Since drug
overuse makes treatment of headache difficult to deal, it is
important to supervise this condition, which is particularly
common in adolescents [110].
Significant progresses in molecular genetics have
advanced our understanding of the genetic basis of mi-
graine and related syndromes, also revealing promising
treatment targets for future drug development. Genetic
findings have revealed ion channels and transporter mu-
tations as causative of migraine [111], which seems to be
related to ionic disturbances with a resultant altered ex-
citability of certain areas of the brain and an age-specific
phenotype.
New technological strategies such as next-generation
sequencing, may aid in the identification of FHM related
genes and promote the research for the missing herit-
ability of common migraine [112]. These platforms are
able to generate more sequence data; they are less ex-
pensive and could help us in finding answers to how
migraine attacks start [113] and what the links with
childhood episodic syndromes are. It is likely that the
study of epigenetic mechanisms (i.e. DNA methylation
and post-translational modifications of histone proteins),
which affect gene expression and cellular responses to
environmental signals, may explain in the next future
how non-genetic triggers may modulate attack frequency
of migraine [114]. It is realistic to imagine that further
studies may reveal tractable drug targets, and this will
also help in the understanding of migraine pathogenic
process, which is essential for a rational development of
effective treatments.
Development of primary headache may be furthered
by environmental conditions [115-117]. A child’s envir-
onment includes home, school, and community and all
of these areas may have profound influences on head-
ache [118]. An association between migraine, parental-
reported emotional problems and self-reported anxiety
suggests that emotional factors may be early contribu-
tors in the pathogenesis of pediatric headache [119,120].
Children with frequents attacks of paroxysmal vertigo
or paroxysmal torticollis are very limited in daytime ac-
tivities and this also influences familial organisation. The
same is true for cyclic vomiting attacks, during which
children are often hospitalized for intravenous rehydra-
tion, and for abdominal migraine, which attacks are
often debilitating and can last for days. When migraine
attacks are too frequent, too long, or too painful, chil-
dren’s quality of life can be affected. Therefore, it could
be useful to assess the level of life quality by validated
scores [121], not only in migraine but also in episodicsyndromes, when possible. Performing a score during
the initial diagnostic assessment can also help in moni-
toring the therapeutic response: changes in score are an
index of the adequacy of undertaken treatment. Several
studies have helped to define the relationship between
psychiatric and psychological co morbidities in children
suffering from migraine and cyclic vomiting. Whether
these comorbidities are triggers or the consequence of a
chronic invalidating condition should be proven further.
Conclusions
Pediatricians are frequently involved in the care of
children and adolescents with headache.
Diagnosing pediatric migraine may be difficult because
of children’s language and cognitive abilities and it is fre-
quently necessary to detect migrainous symptoms from
behaviour. The risk of underestimating the real prevalence
of migraine in pediatric age is high and an adequate
diagnosis is important to limit uncomfortable situations in
school, social and family settings, to maintain a good
quality of life and to avoid inappropriate therapy.
Migraine phenotype differs somewhat in the develop-
ing brain, and childhood episodic syndromes may arise
before typical migraine headache. Being familiar with
the characteristics and evolution of childhood episodic
syndromes may help pediatricians make correct diag-
nosis and give adequate treatments, avoiding unneces-
sary investigations.
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